What is it about?
There has been no standard chemotherapy for recurrent of metastatic salivary gland cancer because of its rarity and complexity of pathological types. Moreover, there have been a few prospective clinical trials for these patients. Hence, we conducted a prospective phase II trial to investigate the efficacy and safety of docetaxel plus cisplatin for the patients with non-squamous cell carcinoma of the head and neck.
Photo by National Cancer Institute on Unsplash
Why is it important?
Docetaxel plus cisplatin is effective for this rare malignancy of non-squamous cell carcinoma of the head and neck including salivary gland cancer.
Read the Original
This page is a summary of: Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial, Medical Oncology, September 2021, Springer Science + Business Media, DOI: 10.1007/s12032-021-01581-z.
You can read the full text:
The following have contributed to this page